- Home
- CLPR vs DTIL Comparison
CLPR vs DTIL Comparison
Compare CLPR & DTIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CLPR | DTIL |
|---|---|---|
| Founded | 2015 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 67.0M | 123.0M |
| IPO Year | 2017 | 2019 |
Fundamental Metrics
Financial Performance| Metric | CLPR | DTIL |
|---|---|---|
| Price | $3.38 | $5.02 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $47.00 |
| AVG Volume (30 Days) | 61.0K | ★ 256.9K |
| Earning Date | 11-13-2025 | 11-03-2025 |
| Dividend Yield | ★ 11.24% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $154,179,000.00 | $698,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $34.30 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 5.90 | N/A |
| 52 Week Low | $3.37 | $3.61 |
| 52 Week High | $6.49 | $8.82 |
Technical Indicators
Market Signals| Indicator | CLPR | DTIL |
|---|---|---|
| Relative Strength Index (RSI) | 31.59 | 40.77 |
| Support Level | $3.57 | $4.70 |
| Resistance Level | $3.65 | $5.54 |
| Average True Range (ATR) | 0.15 | 0.40 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 2.05 | 28.71 |
Price Performance
Historical ComparisonAbout CLPR Clipper Realty Inc.
Clipper Realty Inc is a self-administered and self-managed real estate company. It acquires, owns, manages, operates, and repositions multifamily residential and commercial properties in the New York metropolitan area, with a portfolio in Manhattan and Brooklyn. It has classified its reporting segments into Residential Rental Properties and Commercial Rental Properties. The company derives its revenue mostly from the Residential segment.
About DTIL Precision BioSciences Inc.
Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.